Vol. 6 No. 3 (2026)
Reimbursement Reviews

Teplizumab (Tzield)

decorative image of the issue cover

Published March 18, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Teplizumab (Tzield), 2 mg/2 mL per vial for IV infusion.
  • Indication: To delay the onset of stage 3 T1D in adult and pediatric patients 8 years of age and older with stage 2 T1D.